Medical Condition

pulmonary hypertension

Total Trials

14

Recruiting Now

14

Trial Phases

Phase 3, Phase 1, Phase 2

Hypertension remains the most common treatable cardiovascular risk factor globally, yet blood pressure control rates remain suboptimal despite multiple effective drug classes. Clinical trials now investigate novel mechanisms including aldosterone synthase inhibitors, renal denervation devices, and RNA-based therapies targeting angiotensinogen to achieve durable pressure reduction with minimal pill burden.

Active research includes zilebesiran (RNA interference targeting angiotensinogen), baxdrostat (aldosterone synthase inhibitor), ultrasound renal denervation (Symplicity HTN-4), and resistant hypertension approaches combining SGLT2 inhibitors with MRA spironolactone. Ambulatory blood pressure monitoring is increasingly used as the primary endpoint instead of clinic readings.

Frequently Asked Questions — pulmonary hypertension Clinical Trials

How many clinical trials are currently recruiting for pulmonary hypertension?

ClinicalMetric currently tracks 14 actively recruiting clinical trials for pulmonary hypertension, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 14. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for pulmonary hypertension?

pulmonary hypertension research spans Phase 1 (1 trial), Phase 2 (1 trial), Phase 3 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a pulmonary hypertension clinical trial?

Eligibility criteria for pulmonary hypertension trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

Phase 2

Phase 3

Top Sponsors

Pulnovo Medical (Wuxi) Co., Ltd. 2 trials

University Health Network, Toronto 1 trial

The Hospital for Sick Children 1 trial

Beijing Chao Yang Hospital 1 trial

Alejandro Cruz Utrilla 1 trial

Recruiting Clinical Trials

NCT04901884

Recruiting

PET/MR Pre- and Post Radiotherapy for Cardiopulmonary Dysfunction Evaluation

University Health Network, Tor...

View Trial →

NCT05636397

Recruiting

Safety and PK-PD Study of Oral L-CIT in Preterm Infants With BPD±PH and NEC

The Hospital for Sick Children

View Trial →

NCT06980584

Recruiting

Study on the Treatment of Nonthrombotic Obstructive Pulmonary Hypertension

Beijing Chao Yang Hospital

View Trial →

NCT07236970

Recruiting

Multicenter Study on the Development of Pulmonary Arterial Hypertension Screening Models Based on Artificial Intelligence for Patients With Systemic Sclerosis

Alejandro Cruz Utrilla

View Trial →

NCT05824923 Phase 3

Recruiting

A Trial to Evaluate the Safety and Efficacy of Pulmonary Artery Denervation for the Treatment of Pulmonary Hypertension Associated With Left Heart Failure

Pulnovo Medical (Wuxi) Co., Lt...

View Trial →

NCT07179380 Phase 3

Recruiting

Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Enrollment

344 pts

Location

United States, Argen...

Development of Novel Physiological CMR Methods in Health and Disease

Sheffield Teaching Hospitals N...

View Trial →

NCT05903001

Recruiting

Diaphragmatic Function as a Biomarker

RWTH Aachen University

View Trial →

NCT05329714

Recruiting

PVRI GoDeep Global Deep Phenotyping Meta-Registry for Pulmonary Hypertension

University of Giessen

View Trial →

NCT07224906

Recruiting

Observational Study of Patients Undergoing Diagnostic Right Heart Catheterization

Real-World Study of PADN for the Treatment of PAH

Pulnovo Medical (Wuxi) Co., Lt...

View Trial →

NCT06388421

Recruiting

DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Enrollment

900 pts

Location

United States, Puert...

Pulmonary Hypertension in Left Heart Disease

NCT05746039 Phase 1, Phase 2

Recruiting

Feasibility of Semaglutide in Advanced Lung Disease

University of Pennsylvania

View Trial →

Related Conditions

interstitial lung disease (3) heart failure (2) bpd bronchopulmonary dysplasia (1) nec (1) fibrosing mediastinitis (1) systemic sclerosis ssc (1) systemic sclerosis associated pah (1) heart failure with reduced ejection fraction (1) hypertension (1) vascular diseases (1) cardiovascular diseases (1) heart failure with preserved ejection fraction (1)

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology